1. US Partner: Competitor or Complementary Player?

2. Single partner for several applications or multiple partners per each?

3. Funding options for research projects?

PCCI January 19, 2009

Diana Mackie, Business Dev. Silvia G Codony, Clinical Research

Contura International A/S(Archive Version)

Contura Business Units

For urinary incontinence

PipelineNew applications of soft tissue

filler technologyFor facial augmentation

Contura is a medical technology company based in Denmark focused on developing, manufacturing and commercializing

soft tissue fillers that enhance the quality of people’s lives

Contura is a medical technology company based in Denmark focused on developing, manufacturing and commercializing

soft tissue fillers that enhance the quality of people’s lives

2000: • Contura established

2001: • Aquamid® granted the CE-marking for use in soft tissue facial augmentation

2003: • Bulkamid® granted the CE-marking for use in the treatment of female urinary

incontinence

2004: • Launch of Aquamid® Reconstruction for lipoatrophy, rhinoplasty and volume

correction

2006: • FDA grants Aquamid® I D E, allowing its use in a major comparative clinical

trial in the United States

2007: • Contura and ETHICON, a J & J company, sign agreement granting ETHICON

exclusive worldwide distribution rights for Bulkamid®.

• Contura’s United States subsidiary Contura Inc. established

• Contura awarded the Product Differentiation Innovation Award for Aquamid® by

Frost & Sullivan

2008: • Clinical trial of Bulkamid® in the United States begins

• New manufacturing facility completed

Contura History and Milestones

Aesthetic Filler Market

Aquamid® Positioning

Aquamid® Pivotal Clinical Trial Results

Partnership Opportunity

US Aesthetics Filler Market

Total Aesthetics Medicine market size exceeds $13 Billion* – Surgical procedures $  8.4 B

– Non-Surgical procedures $  4.8 B

Non-Surgical Procedures market size, includes MD fees & product– Botox > $ 1 B

– All soft tissue fillers $ 1 B

Number of Procedures– Botox 4.6 M $350 M at office retail

– Soft Tissue Fillers 1.5 M $350 M at office retail

* Source: Data from 2007 ASAPS and the May 2008 Millenium Research Group Report

Market Dynamics: Many New Introductions

2004 2005 2006 2007 2008 2009

Radiesse Elevess relaunch Restylane Sculptra Juvederm Evolence Artefill (Puragen), Perlane Prevelle___▼_______▼________________▼_▼_▼_▼______▼_▼_▼▼__________►

Sources: industry studies, publications, company information Hyaluronic Acid brands (HAs) , Particle and Polymer brands (PPFs), Collagen brand

After cannibalizing Collagen, HA growth was blunted.

Number of procedures

0

200000

400000

600000

800000

1000000

1200000

1400000

1600000

1800000

2003 2004 2005 2006 2007

Collagen

Auto. Fat

Hyaluronic Acid

Radiesse

Sculptra

Artefill

Source: ASAPS

(ASPS data show same effect)

Competitive PlayersPortfolio Approach in high gear

• Allergan: Botox + very successful launch of Juvederm line

• Mentor: PurTox + Prevelle Silk launch + PLEs (acquired by J&J)

• BioForm: Radiesse + Relaxed Expressions (RF technique alternative to neurotoxin)

• Medicis: Neurotoxin + Restylane line

• Artes Medical: Elevess (HA) + Artefill long duration filler (now in Chapter 7)

Bundling promotions is a key factor for success and is believed to help hold physicians loyal to your line.

Aesthetic Filler Market

Aquamid® Positioning

Aquamid® Pivotal Clinical Trial Results

Partnership Opportunity

US Aesthetics Filler Market

Total Aesthetics Medicine market size exceeds $13 Billion* – Surgical procedures $  8.4 B

– Non-Surgical procedures $  4.8 B

Non-Surgical Procedures market size, includes MD fees & product– Botox > $ 1 B

– All soft tissue fillers $ 1 B

Number of Procedures– Botox 4.6 M $350 M at office retail

– Soft Tissue Fillers 1.5 M $350 M at office retail

* Source: Data from 2007 ASAPS and the May 2008 Millenium Research Group Report

Market Dynamics: Many New Introductions

2004 2005 2006 2007 2008 2009

Radiesse Elevess relaunch Restylane Sculptra Juvederm Evolence Artefill (Puragen), Perlane Prevelle___▼_______▼________________▼_▼_▼_▼______▼_▼_▼▼__________►

Sources: industry studies, publications, company information Hyaluronic Acid brands (HAs) , Particle and Polymer brands (PPFs), Collagen brand

After cannibalizing Collagen, HA growth was blunted.

Number of procedures

0

200000

400000

600000

800000

1000000

1200000

1400000

1600000

1800000

2003 2004 2005 2006 2007

Collagen

Auto. Fat

Hyaluronic Acid

Radiesse

Sculptra

Artefill

Source: ASAPS

(ASPS data show same effect)

Competitive PlayersPortfolio Approach in high gear

• Allergan: Botox + very successful launch of Juvederm line

• Mentor: PurTox + Prevelle Silk launch + PLEs (acquired by J&J)

• BioForm: Radiesse + Relaxed Expressions (RF technique alternative to neurotoxin)

• Medicis: Neurotoxin + Restylane line

• Artes Medical: Elevess (HA) + Artefill long duration filler (now in Chapter 7)

Bundling promotions is a key factor for success and is believed to help hold physicians loyal to your line.

Neurotoxin Collagen Hyaluronic Acids

Longer

Lasting

Allergan YES YES YES

Medicis (Pipeline) YES

Mentor +

JnJ

(Pipeline) YES YES

BioForm Relaxed

Expressions

YES

Artes Medical

YES YES

Each company started from one box and has been acquiring to complete the portfolio

Aquamid characteristics:- Non-degradable - Biocompatible, Non-migrational- Non-allergenic, atoxic- Homogeneous (no particles)- Exchanges water, salts and organic molecules with host tissue- Stored without refrigeration

Mode of Action -Volumizer – No intended foreign body reaction -full integration and vascularization

Aquamid Has Unique Properties and Benefits

Aquamid is an injectable hydrogel consisting of 97.5% water and 2.5% cross-linked polyacrylamide (1 ml syringe/27G needle)

Facial skin sags → Surgical Facelift

Loss of subcutaneous fat tissue → volume filler“Boosting volume under the skin”

Wrinkles & folds in lower face → dermal fillers

Lines & wrinkles in upper face → neurotoxins

Ageing

Young

Old

New Trend: Volume Filling and Facial Sculpting

Unique Benefits of Aquamid®

Versatile volumizer: well suited for volumizing and sculpting procedures. Directed to the subcutaneous tissue for immediate filling and lifting effect.

Natural look and feel: The gel is homogeneous. Aquamid® does not induce inflammatory nodules or granulomas. Integrates completely with existing tissue.

Lasting enhancement: non-resorbable and enduring augmentation. Clinical data demonstrate patient and investigator satisfaction that exceeds 90% after 5 years.

Naso labial folds

Lip augmentation

Cheek contouring

Mento labial folds

Glabella filling

Nose correction

Chin augmentation

Scar correction

Facial augmentation to correct lipoatrophy

Minor body contouring

Aquamid® Versatile in Applications

Durability of augmentation

Compatibility with tissue

Evolence

Soft Tissue Filler Positionings

Artefill

Sculptra Radiesse

Juvederm

Restylane

Aquamid® Pivotal US Study Results

Study Design

Results Highlights– Effectiveness– Safety

Study Design

Aquamid® – 210 subjects

Restylane® – 105 subjects

Screening

Treatment to Optimal Max 3 sessions

3M 6M 9M 12M

Treated area: nasolabial folds

13 Sites in the US – each with 19 - 33 subjects

Pivotal Study Key Conclusions

Successfully show that Aquamid® is safe and effective for its intended use.

Support the regulatory requirements for the PMA filing

Market Outlook

Flat to low growth through 1H 2009 due to economy and less DTC advertising for next 6 months – however Botox grew by 13% in a challenging Q4/2008

New aesthetic medicines will launch, about one per year. Premium place given to those that leverage a sales force in place and where bundling can occur

Aquamid® launch in 2010 should find an industry in growth again with receptive physicians and consumers.

Partnership Opportunity

Contura is seeking a US Marketing partner via a US/NA license to commercialize Aquamid® to its target customers.

The framework of a marketing plan is available and shows how Aquamid® would roll out to experienced and trained physicians in soft tissue fillers

Aquamid® will sustain an appropriate price premium.

Supply and further development to come from Contura A/S

Other Potential Partners for Aquamid® Beyond Current Filler Competitors

Therapeutic Dermatology Focus Aesthetic Equipment/Device Focus

Galderma Graceway

American Laser Angiotech Pharma

Merz Nycomed

Cynosure New Star Lasers

Obagi

KIng

PhotoMedex Syneron

SkinMedica Stiefel

Consumer Companies in OTC Derm

Valeant P&G J&J

DermaPlus DermaVance

Schering-Plough Unilever